Barbara Tilley to Humans
This is a "connection" page, showing publications Barbara Tilley has written about Humans.
Connection Strength
0.984
-
Using increased trust in medical researchers to increase minority recruitment: The RECRUIT cluster randomized clinical trial. Contemp Clin Trials. 2021 10; 109:106519.
Score: 0.029
-
Recruitment of racial and ethnic minorities to clinical trials conducted within specialty clinics: an intervention mapping approach. Trials. 2018 Feb 17; 19(1):115.
Score: 0.023
-
Design of a cluster-randomized minority recruitment trial: RECRUIT. Clin Trials. 2017 Jun; 14(3):286-298.
Score: 0.022
-
Continuous time Markov chain approaches for analyzing transtheoretical models of health behavioral change: A case study and comparison of model estimations. Stat Methods Med Res. 2018 02; 27(2):593-607.
Score: 0.020
-
Analysis of transtheoretical model of health behavioral changes in a nutrition intervention study--a continuous time Markov chain model with Bayesian approach. Stat Med. 2015 Nov 30; 34(27):3577-89.
Score: 0.019
-
Erythropoietin for traumatic brain injury--reply. JAMA. 2014 Nov 12; 312(18):1929.
Score: 0.018
-
Enrollment of racially/ethnically diverse participants in traumatic brain injury trials: effect of availability of exception from informed consent. Clin Trials. 2014 Apr; 11(2):187-94.
Score: 0.018
-
Using cognitive pretesting in scale development for Parkinson's disease: the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) example. J Parkinsons Dis. 2014; 4(3):395-404.
Score: 0.017
-
How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord. 2013 May; 28(5):668-70.
Score: 0.016
-
Unequal burden of disease, unequal participation in clinical trials: solutions from African American and Latino community members. Health Soc Work. 2013 Feb; 38(1):29-38.
Score: 0.016
-
Bayesian multiple imputation for missing multivariate longitudinal data from a Parkinson's disease clinical trial. Stat Methods Med Res. 2016 04; 25(2):821-37.
Score: 0.016
-
Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores. Mov Disord. 2012 Sep 01; 27(10):1239-42.
Score: 0.016
-
Contemporary outcome measures in acute stroke research: choice of primary outcome measure and statistical analysis of the primary outcome in acute stroke trials. Stroke. 2012 Apr; 43(4):935-7.
Score: 0.015
-
Secondary analyses in cardiovascular clinical trials - statistical and other considerations. Introduction. Prog Cardiovasc Dis. 2012 Jan-Feb; 54(4):329.
Score: 0.015
-
Economic analysis of secondary trial data. Prog Cardiovasc Dis. 2012 Jan-Feb; 54(4):351-6.
Score: 0.015
-
Examining the role of perceived susceptibility on colorectal cancer screening intention and behavior. Ann Behav Med. 2010 Oct; 40(2):205-17.
Score: 0.014
-
Repeatable battery for assessment of neuropsychological status in early Parkinson's disease. Mov Disord. 2009 Jul 30; 24(10):1453-60.
Score: 0.013
-
Retention of under-represented minorities in drug abuse treatment studies. Clin Trials. 2009 Jun; 6(3):252-60.
Score: 0.013
-
Factors influencing physician referrals of patients to clinical trials. J Natl Med Assoc. 2008 Nov; 100(11):1298-303.
Score: 0.012
-
Minority enrollment in Parkinson's disease clinical trials. Parkinsonism Relat Disord. 2009 May; 15(4):258-62.
Score: 0.012
-
Factor analysis of the Repeatable Battery for the Assessment of Neuropsychological Status. Appl Neuropsychol. 2008; 15(4):274-9.
Score: 0.011
-
A coronary heart disease risk score based on patient-reported information. Am J Cardiol. 2007 May 01; 99(9):1236-41.
Score: 0.011
-
Correlates and predictors of colorectal cancer screening among male automotive workers. Cancer Epidemiol Biomarkers Prev. 2007 Mar; 16(3):500-9.
Score: 0.011
-
Screening potential therapies: lessons learned from new paradigms used in Parkinson disease. Stroke. 2007 Feb; 38(2 Suppl):800-3.
Score: 0.011
-
A study of lower extremity amputation rates in older diabetic South Carolinians. J S C Med Assoc. 2007 Feb; 103(1):4-7.
Score: 0.011
-
English language skills and diabetes and hypertension among foreign-born South Asian adults in England. Public Health Rep. 2006 May-Jun; 121(3):331-6.
Score: 0.010
-
Development of a measure to assess patient trust in medical researchers. Ann Fam Med. 2006 May-Jun; 4(3):247-52.
Score: 0.010
-
Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology. 2006 Mar 14; 66(5):628-33.
Score: 0.010
-
Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. J Rheumatol. 2005 Oct; 32(10):1888-92.
Score: 0.010
-
Quasi-likelihood estimation for relative risk regression models. Biostatistics. 2005 Jan; 6(1):39-44.
Score: 0.009
-
Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials. 2005; 2(6):509-18.
Score: 0.009
-
Race, education, and knowledge of bone marrow registry: indicators of willingness to donate bone marrow among African Americans and Caucasians. Transplant Proc. 2004 Dec; 36(10):3212-9.
Score: 0.009
-
An efficient multi-stage, single-arm Phase II futility design for ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep; 5 Suppl 1:55-6.
Score: 0.009
-
Clinical trials, outcome measures, and response criteria. J Rheumatol. 2004 Mar; 31(3):407-10.
Score: 0.009
-
A pilot study of health education via a nurse-run telephone self-management programme for elderly people with osteoarthritis. J Telemed Telecare. 2004; 10(1):44-9.
Score: 0.009
-
Intention to be screened over time for colorectal cancer in male automotive workers. Cancer Epidemiol Biomarkers Prev. 2003 Apr; 12(4):339-49.
Score: 0.008
-
Recruiting older African American men to a cancer screening trial (the AAMEN Project). Gerontologist. 2003 Feb; 43(1):27-35.
Score: 0.008
-
Improving health outcomes in diverse and vulnerable populations: building on the experience of the Centers for Medical Treatment Effectiveness in Diverse Populations (MEDTEP). Ethn Health. 2002 Nov; 7(4):227-30.
Score: 0.008
-
Perceptions of diabetes among patients in an urban health care system. Ethn Health. 2002 Nov; 7(4):243-54.
Score: 0.008
-
Recruitment of African Americans with type 2 diabetes to a randomized controlled trial using three sources. Ethn Health. 2002 Nov; 7(4):267-78.
Score: 0.008
-
Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial. Trials. 2022 Oct 06; 23(1):855.
Score: 0.008
-
Inclusion of Non-English-Speaking Participants in Studies of Parkinson's Disease: A Call to Action. Mov Disord. 2022 10; 37(10):1990-1995.
Score: 0.008
-
Intent-to-treat analysis of cluster randomized trials when clusters report unidentifiable outcome proportions. Clin Trials. 2020 12; 17(6):627-636.
Score: 0.007
-
Cost-effectiveness evaluation of the PROPPR trial transfusion protocols. Transfusion. 2020 05; 60(5):922-931.
Score: 0.007
-
Global statistical tests for comparing multiple outcomes in rheumatoid arthritis trials. MIRA Trial Group. Arthritis Rheum. 1999 Sep; 42(9):1879-88.
Score: 0.006
-
The Next Step Trial: impact of a worksite colorectal cancer screening promotion program. Prev Med. 1999 Mar; 28(3):276-83.
Score: 0.006
-
Nutrition intervention for high-risk auto workers: results of the Next Step Trial. Prev Med. 1999 Mar; 28(3):284-92.
Score: 0.006
-
Hypertension and its treatment in the NINDS rt-PA Stroke Trial. Stroke. 1998 Aug; 29(8):1504-9.
Score: 0.006
-
Racial differences in emergency department use persist despite allergist visits and prescriptions filled for antiinflammatory medications. J Allergy Clin Immunol. 1998 Apr; 101(4 Pt 1):484-90.
Score: 0.006
-
Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Arch Neurol. 1997 Dec; 54(12):1466-74.
Score: 0.006
-
Myths regarding the NINDS rt-PA Stroke Trial: setting the record straight. Ann Emerg Med. 1997 Nov; 30(5):676-82.
Score: 0.006
-
Development and validation of an instrument to measure factors related to colorectal cancer screening adherence. Cancer Epidemiol Biomarkers Prev. 1997 Oct; 6(10):825-32.
Score: 0.006
-
Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord. 2017 Dec; 45:7-12.
Score: 0.006
-
Benefits of stroke treatment delivered using a mobile stroke unit trial. Int J Stroke. 2018 04; 13(3):321-327.
Score: 0.005
-
Comparison of laboratory test frequency and test results between African-Americans and Caucasians with diabetes: opportunity for improvement. Findings from a large urban health maintenance organization. Diabetes Care. 1997 Jun; 20(6):971-7.
Score: 0.005
-
Earlier Endpoints are Required for Hemorrhagic Shock Trials Among Severely Injured Patients. Shock. 2017 05; 47(5):567-573.
Score: 0.005
-
Autonomic and electrocardiographic findings in Parkinson's disease. Auton Neurosci. 2017 07; 205:93-98.
Score: 0.005
-
Worksite cancer screening and nutrition intervention for high-risk auto workers: design and baseline findings of the Next Step Trial. Prev Med. 1997 Mar-Apr; 26(2):227-35.
Score: 0.005
-
Damage control laparotomy utilization rates are highly variable among Level I trauma centers: Pragmatic, Randomized Optimal Platelet and Plasma Ratios findings. J Trauma Acute Care Surg. 2017 03; 82(3):481-488.
Score: 0.005
-
Caffeine, creatine, GRIN2A and Parkinson's disease progression. J Neurol Sci. 2017 Apr 15; 375:355-359.
Score: 0.005
-
Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An?Analysis?of?NET-PD LS1. J Parkinsons Dis. 2017; 7(1):117-127.
Score: 0.005
-
Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale. Mov Disord. 2016 12; 31(12):1865-1873.
Score: 0.005
-
Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. Stroke. 1996 Nov; 27(11):2136-42.
Score: 0.005
-
HLA-DRB1 genes and disease severity in rheumatoid arthritis. The MIRA Trial Group. Minocycline in Rheumatoid Arthritis. Arthritis Rheum. 1996 Nov; 39(11):1802-7.
Score: 0.005
-
Religiosity in black and white older Americans: Measure adaptation, psychometric validation, and racial difference. Medicine (Baltimore). 2016 Sep; 95(37):e4257.
Score: 0.005
-
Communicating with participants during the conduct of multi-center clinical trials. Clin Trials. 2016 12; 13(6):592-596.
Score: 0.005
-
Assessing protocol adherence in a clinical trial with ordered treatment regimens: Quantifying the pragmatic, randomized optimal platelet and plasma ratios (PROPPR) trial experience. Injury. 2016 Oct; 47(10):2131-2137.
Score: 0.005
-
Two Decades of ICU Utilization and Hospital Outcomes in a Comprehensive Cancer Center. Crit Care Med. 2016 May; 44(5):926-33.
Score: 0.005
-
Damage-control resuscitation and emergency laparotomy: Findings from the PROPPR study. J Trauma Acute Care Surg. 2016 Apr; 80(4):568-74; discussion 574-5.
Score: 0.005
-
An empowerment-centered, church-based asthma education program for African American adults. Health Soc Work. 1996 Feb; 21(1):70-5.
Score: 0.005
-
The incidence of ARDS and associated mortality in severe TBI using the Berlin definition. J Trauma Acute Care Surg. 2016 Feb; 80(2):308-12.
Score: 0.005
-
Association of transfusion red blood cell storage age and blood oxygenation, long-term neurologic outcome, and mortality in traumatic brain injury. J Trauma Acute Care Surg. 2015 Nov; 79(5):843-9.
Score: 0.005
-
Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio. Cerebrovasc Dis. 2015; 40(5-6):293-300.
Score: 0.005
-
Planning the next step. A screening promotion and nutrition intervention trial in the work site. Ann N Y Acad Sci. 1995 Sep 30; 768:296-9.
Score: 0.005
-
Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. Clin Neuropharmacol. 2015 Sep-Oct; 38(5):163-9.
Score: 0.005
-
Place of Death among Hospitalized Patients with Cancer at the End of Life. J Palliat Med. 2015 Aug; 18(8):667-76.
Score: 0.005
-
Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: experience from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) trial. Transfusion. 2015 Jun; 55(6):1331-9.
Score: 0.005
-
Effect of Hemoglobin Transfusion Threshold on Cerebral Hemodynamics and Oxygenation. J Neurotrauma. 2015 Aug 15; 32(16):1239-45.
Score: 0.005
-
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93.
Score: 0.005
-
Handling missing values in the MDS-UPDRS. Mov Disord. 2015 Oct; 30(12):1632-8.
Score: 0.005
-
Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015 Feb 03; 313(5):471-82.
Score: 0.005
-
Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med. 1995 Jan 15; 122(2):81-9.
Score: 0.005
-
An evaluation of differences in risk factors for individual types of surgical site infections after colon surgery. Surgery. 2014 Nov; 156(5):1253-60.
Score: 0.005
-
Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. Parkinsonism Relat Disord. 2014 Nov; 20(11):1135-9.
Score: 0.005
-
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014 Nov 29; 384(9958):1929-35.
Score: 0.004
-
Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial. JAMA. 2014 Jul 02; 312(1):36-47.
Score: 0.004
-
Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: design, rationale and implementation. Injury. 2014 Sep; 45(9):1287-95.
Score: 0.004
-
Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. JAMA Neurol. 2014 Jun; 71(6):710-6.
Score: 0.004
-
Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients. Eur J Neurol. 2014 Mar; 21(3):519-24.
Score: 0.004
-
The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. Parkinsonism Relat Disord. 2013 Oct; 19(10):889-93.
Score: 0.004
-
Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale. Eur J Neurol. 2015 Jan; 22(1):37-43.
Score: 0.004
-
The health education for lupus study: a randomized controlled cognitive-behavioral intervention targeting psychosocial adjustment and quality of life in adolescent females with systemic lupus erythematosus. Am J Med Sci. 2012 Oct; 344(4):274-82.
Score: 0.004
-
Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol. 2013 Jan; 260(1):228-36.
Score: 0.004
-
Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. Neurol Sci. 2013 May; 34(5):683-7.
Score: 0.004
-
Fall frequency and risk assessment in early Parkinson's disease. Parkinsonism Relat Disord. 2012 Aug; 18(7):837-41.
Score: 0.004
-
The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop. Transfusion. 2012 Jun; 52(6):1363-78.
Score: 0.004
-
A randomized recruitment intervention trial in Parkinson's disease to increase participant diversity: early stopping for lack of efficacy. Clin Trials. 2012 Apr; 9(2):188-97.
Score: 0.004
-
Outcome variables in osteoporosis trials. Bone. 1992; 13 Suppl 1:S29-34.
Score: 0.004
-
Dopamine dysregulation syndrome item from the MDS-UPDRS. Mov Disord. 2012 Jan; 27(1):166.
Score: 0.004
-
Subject-investigator reproducibility of the Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord. 2012 Mar; 18(3):230-3.
Score: 0.004
-
Pitfalls in the quest of neuroprotectants for the perinatal brain. Dev Neurosci. 2011; 33(3-4):189-98.
Score: 0.004
-
Application of beta regression to analyze ischemic stroke volume in NINDS rt-PA clinical trials. Neuroepidemiology. 2011; 37(2):73-82.
Score: 0.004
-
Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord. 2010 Dec 15; 25(16):2704-16.
Score: 0.003
-
Designing clinical trials of treatment for osteoporosis: recruitment and follow-up. Calcif Tissue Int. 1990 Dec; 47(6):327-31.
Score: 0.003
-
Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease. Mov Disord. 2010 Jun 15; 25(8):1082-6.
Score: 0.003
-
Risk of colorectal cancer among automotive pattern and model makers. J Occup Med. 1990 Jun; 32(6):541-6.
Score: 0.003
-
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010 May 15; 375(9727):1695-703.
Score: 0.003
-
A meta-analysis of exposure to phenoxy acid herbicides and chlorophenols in relation to risk of soft tissue sarcoma. Int Arch Occup Environ Health. 1990; 62(7):513-20.
Score: 0.003
-
Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord. 2009 Sep 15; 24(12):1732-9.
Score: 0.003
-
Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. Arch Neurol. 2009 Sep; 66(9):1099-104.
Score: 0.003
-
Patent foramen ovale, cardiac valve thickening, and antiphospholipid antibodies as risk factors for subsequent vascular events: the PICSS-APASS study. Stroke. 2009 Jul; 40(7):2337-42.
Score: 0.003
-
Two pharmacy interventions to improve refill persistence for chronic disease medications: a randomized, controlled trial. Med Care. 2009 Jan; 47(1):32-40.
Score: 0.003
-
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
Score: 0.003
-
Caffeine and progression of Parkinson disease. Clin Neuropharmacol. 2008 Jul-Aug; 31(4):189-96.
Score: 0.003
-
Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience. Mov Disord. 2007 Apr 30; 22(6):822-7.
Score: 0.003
-
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7.
Score: 0.003
-
Mentoring in community-based participatory research: the RCMAR experience. Ethn Dis. 2007; 17(1 Suppl 1):S33-43.
Score: 0.003
-
Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke. 2006 Oct; 37(10):2508-13.
Score: 0.003
-
Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke. 2006 Jul; 37(7):1798-804.
Score: 0.003
-
Lessons from adult stroke trials. Pediatr Neurol. 2006 Jun; 34(6):446-9.
Score: 0.003
-
Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol. 2006 Feb; 33(2):263-8.
Score: 0.002
-
Acculturation and diabetes among Hispanics: evidence from the 1999-2002 National Health and Nutrition Examination Survey. Public Health Rep. 2006 Jan-Feb; 121(1):60-6.
Score: 0.002
-
Applying a phase II futility study design to therapeutic stroke trials. Stroke. 2005 Nov; 36(11):2410-4.
Score: 0.002
-
Nonprescribed antimicrobial drugs in Latino community, South Carolina. Emerg Infect Dis. 2005 Jun; 11(6):883-8.
Score: 0.002
-
Adjusting O'Brien's test to control type I error for the generalized nonparametric Behrens-Fisher problem. Biometrics. 2005 Jun; 61(2):532-9.
Score: 0.002
-
The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study. Ann Emerg Med. 2005 Apr; 45(4):377-84.
Score: 0.002
-
A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb; 57(2):197-203.
Score: 0.002
-
Clinical trials: II. Randomization and sample size. Henry Ford Hosp Med J. 1985; 33(4):219-24.
Score: 0.002
-
Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis. J Rheumatol. 2005 Jan; 32(1):51-7.
Score: 0.002
-
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004 Mar 06; 363(9411):768-74.
Score: 0.002
-
Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004 Feb 04; 291(5):576-84.
Score: 0.002
-
An assessment of racial differences in clinical practices for hypertension at primary care sites for medically underserved patients. J Clin Hypertens (Greenwich). 2004 Jan; 6(1):26-31; quiz 32-3.
Score: 0.002
-
Antiphospholipid-protein antibodies and acute ischemic stroke in the NINDS rt-PA Stroke Trial. Neurology. 2003 Oct 28; 61(8):1158-9.
Score: 0.002
-
Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke. 2003 Aug; 34(8):e109-37.
Score: 0.002
-
Pilot clinical trial of intravenous doxycycline versus placebo for rheumatoid arthritis. J Rheumatol. 2003 Jan; 30(1):41-3.
Score: 0.002
-
Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology. 2002 Sep 10; 59(5):669-74.
Score: 0.002
-
Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA. 2001 Dec 12; 286(22):2830-8.
Score: 0.002
-
Use of odds ratio or relative risk to measure a treatment effect in clinical trials with multiple correlated binary outcomes: data from the NINDS t-PA stroke trial. Stat Med. 2001 Jul 15; 20(13):1891-901.
Score: 0.002
-
Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000 Dec 12; 55(11):1649-55.
Score: 0.002
-
Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial. Neurology. 2000 Oct 10; 55(7):952-9.
Score: 0.002
-
Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke. 2000 Oct; 31(10):2335-41.
Score: 0.002
-
Mediating factors in dietary change: understanding the impact of a worksite nutrition intervention. Health Educ Behav. 2000 Feb; 27(1):112-25.
Score: 0.002
-
Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. Stroke. 1999 Aug; 30(8):1528-33.
Score: 0.002
-
Nurses' perceptions: issues that arise in caring for patients with diabetes. J Adv Nurs. 1999 Aug; 30(2):425-30.
Score: 0.002
-
Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med. 1999 Jun 10; 340(23):1781-7.
Score: 0.002
-
Self-administered joint counts and standard joint counts in the assessment of rheumatoid arthritis. MIRA Trial Group. Minocycline in RA. J Rheumatol. 1999 May; 26(5):1065-7.
Score: 0.002
-
Guidelines for the management of spontaneous intracerebral hemorrhage: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 1999 Apr; 30(4):905-15.
Score: 0.002
-
Lower thrombolytic use for African Americans with myocardial infarction: an influence of clinical presentation? Am Heart J. 1999 Feb; 137(2):338-45.
Score: 0.002
-
A comparison of asthma-related healthcare use between African-Americans and Caucasians belonging to a health maintenance organization (HMO). J Asthma. 1999; 36(2):195-204.
Score: 0.002
-
Social support among African-American adults with diabetes, Part 2: A review. J Natl Med Assoc. 1998 Jul; 90(7):425-32.
Score: 0.001
-
Social support among African-American adults with diabetes. Part 1: Theoretical framework. J Natl Med Assoc. 1998 Jun; 90(6):361-5.
Score: 0.001
-
Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998 Apr; 50(4):883-90.
Score: 0.001
-
Intention to screen for colorectal cancer among white male employees. Prev Med. 1998 Mar-Apr; 27(2):279-87.
Score: 0.001
-
Psychosocial correlates of healthful diets among male auto workers. Cancer Epidemiol Biomarkers Prev. 1998 Feb; 7(2):119-26.
Score: 0.001
-
Quality of life, medication use, and health care utilization of urban African Americans with asthma treated in emergency departments. Nurs Res. 1997 Nov-Dec; 46(6):338-41.
Score: 0.001
-
Health outcomes among African American and Caucasian adults following a randomized trial of an asthma education program. Ethn Health. 1997 Nov; 2(4):329-39.
Score: 0.001
-
A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. Minocycline in Rheumatoid Arthritis Trial Group. J Rheumatol. 1997 Oct; 24(10):1910-5.
Score: 0.001
-
Radiographic results from the Minocycline in Rheumatoid Arthritis (MIRA) Trial. J Rheumatol. 1997 Jul; 24(7):1295-302.
Score: 0.001
-
Meaningful improvement criteria sets in a rheumatoid arthritis clinical trial. MIRA Trial Group. Minocycline in Rheumatoid Arthritis. Arthritis Rheum. 1997 Mar; 40(3):419-25.
Score: 0.001
-
Another look at minocycline. Bull Rheum Dis. 1996 Dec; 45(8):6-7.
Score: 0.001
-
Rib enlargement in patients with chronic pleural disease. AJR Am J Roentgenol. 1996 Oct; 167(4):921-6.
Score: 0.001
-
Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke. 1994 Nov; 25(11):2220-6.
Score: 0.001
-
Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. Genes Chromosomes Cancer. 1994 Mar; 9(3):192-206.
Score: 0.001
-
Prognostic significance of electrocardiographic persistent ST depression in patients with their first myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. Am Heart J. 1993 Aug; 126(2):271-8.
Score: 0.001
-
Age-related changes in glomerular volume and hydroxyproline content in rat and human. J Am Soc Nephrol. 1992 Jun; 2(12):1716-25.
Score: 0.001
-
Natural history of the first non-Q wave myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. Am Heart J. 1991 Dec; 122(6):1548-53.
Score: 0.001
-
The cost and effectiveness of an education program for adults who have asthma. J Gen Intern Med. 1991 Sep-Oct; 6(5):401-7.
Score: 0.001
-
A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int. 1991 Jun; 1(3):155-61.
Score: 0.001
-
Subgroup analysis of clinical trials. Am J Cardiol. 1991 Feb 01; 67(4):330-2.
Score: 0.001
-
Effects of propranolol in non-Q-wave acute myocardial infarction in the beta blocker heart attack trial. Am J Cardiol. 1990 Jul 15; 66(2):129-33.
Score: 0.001
-
Measurement of vertebral area on spine x-rays in osteoporosis: reliability of digitizing techniques. J Bone Miner Res. 1990 Jul; 5(7):707-16.
Score: 0.001
-
Effects of cigarette smoking and propranolol in survivors of acute myocardial infarction. Am J Cardiol. 1990 Feb 01; 65(5):271-6.
Score: 0.001
-
Identification of women at risk for developing postmenopausal osteoporosis with vertebral fractures: role of history and single photon absorptiometry. Bone Miner. 1989 Sep; 7(2):171-86.
Score: 0.001
-
Risk identification at the time of admission to coronary care unit in patients with suspected myocardial infarction. Am Heart J. 1988 Nov; 116(5 Pt 1):1212-7.
Score: 0.001
-
Recurrent femoral anastomotic aneurysms. A 30-year experience. Ann Surg. 1988 Oct; 208(4):401-9.
Score: 0.001
-
Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease. Chest. 1988 Jul; 94(1):44-8.
Score: 0.001
-
Cerebral blood flow asymmetry in the detection of extracranial cerebrovascular disease. Stroke. 1988 Jul; 19(7):813-9.
Score: 0.001
-
Efficacy of propranolol therapy after acute myocardial infarction related to coronary arterial anatomy and left ventricular function. Am J Cardiol. 1987 Nov 01; 60(13):976-80.
Score: 0.001
-
Marital status, delay in seeking treatment and survival from breast cancer. Soc Sci Med. 1986; 23(3):305-12.
Score: 0.001
-
Ethnicity, survival, and delay in seeking treatment for symptoms of breast cancer. Cancer. 1985 Apr 01; 55(7):1563-71.
Score: 0.001
-
The porcine bioprosthetic valve. Twelve years later. J Thorac Cardiovasc Surg. 1985 Apr; 89(4):499-507.
Score: 0.001
-
Design and preliminary observations of National Cooperative Diethylstilbestrol Adenosis (DESAD) Project. Obstet Gynecol. 1978 Apr; 51(4):453-8.
Score: 0.000